TARA — Protara Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1359931 ·
Last close
$3.92
Market Cap
$220.32M
52W High
$5.68
52W Low
$3.62
ADV30
630,813
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -19,629,000 | -17,782,000 | 191,923,000 | 14,737,000 | 10,715,000 |
| Dec 2025 | 0 | — | -19,079,000 | -17,307,000 | 209,468,000 | 49,657,000 | 13,056,000 |
| Sep 2025 | 0 | — | -14,760,000 | -13,258,000 | 144,636,000 | 12,551,000 | 12,345,000 |
| Jun 2025 | 0 | — | -16,586,000 | -14,960,000 | 156,933,000 | 31,496,000 | 12,510,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,995,000
Investing CF
$-95,858,000
Financing CF
$82,129,000
CapEx
$-94,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-320,201,000
Inventory
—
Receivables
$1,517,000
ST Investments
$121,049,000
EBIT TTM
$-70,054,000
Pretax Income TTM
$-63,307,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -64,549,000 | -57,439,000 | 209,468,000 | 13,056,000 | — | -56,365,000 |
| Dec 2024 | 0 | -49,154,000 | -44,596,000 | 181,454,000 | 14,320,000 | — | -35,808,000 |
| Dec 2023 | 0 | -43,613,000 | -40,420,000 | 78,954,000 | 10,633,000 | — | -37,557,000 |
| Dec 2022 | 0 | -37,545,000 | -65,952,000 | 113,290,000 | 11,207,000 | — | -26,457,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.64
Max Pain — expiry 2026-08-21
max pain strike: $5.00 · spot: $3.92 · call oi: 1,314 · put oi: 263
Expected Move to 2026-08-21:
±$1.20
(30.61%) —
implied range
$2.72 –
$5.12
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGEN | COMPUGEN LTD | $222.27M | $2.35 | — |
| CHRS | Coherus Oncology, Inc. | $217.49M | $1.41 | — |
| CLLS | Cellectis S.A. | $199.92M | $2.75 | — |
| PLX | Protalix BioTherapeutics, Inc. | $190.95M | $2.37 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $254.85M | $2.75 | — |
News headlines (Yahoo Finance, 1h cache)
What Makes Protara Therapeutics (TARA) a New Buy Stock
2026-07-21 16:00 · Yahoo
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
2026-06-23 14:31 · Yahoo
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
2026-05-31 14:39 · Yahoo
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
2026-05-20 12:00 · Yahoo
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
2026-05-18 12:00 · Yahoo
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
2026-05-15 11:00 · Yahoo
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
2026-05-13 12:00 · Yahoo
One Protara Therapeutics Insider Raised Their Stake In The Previous Year
2026-05-04 10:15 · Yahoo
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
2026-04-27 20:05 · Yahoo
Protara Therapeutics: Q4 Earnings Snapshot
2026-03-10 12:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.